Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CD38 monoclonal antibody felzartamab for late antibody-mediated rejection: a phase II drug evaluation

1 Feb 2025

Abstract excerpt

Introduction Felzartamab is a novel, fully human CD38 monoclonal antibody, currently in development for the treatment of antibody-mediated rejection (AMR) following kidney transplantation.Areas covered This review focuses on current phase II trials of felzartamab in AMR and other immune-mediated kidney diseases. Specifically, it discusses the drug’s mechanism of action, current phase of clinical development,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine and Purinergic Signaling
Share to Blood groups and transfusion
Share to Renal Transplantation Outcomes and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39925214
DOI: 10.1080/13543784.2025.2463092

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CD38 monoclonal antibody felzartamab for late antibody-mediated rejection: a phase II drug evaluationPMID 39925214Read ↗

Effect of felzartamab anti-CD38 treatment on the molecular phenotype of antibody-mediated rejection in kidney transplant biopsies.Semantic proximity Read ↗

Targeting CD38 Across Autoimmune and Plasma Cell–Driven Immune-Mediated Diseases: Rationale, Clinical Evidence, and Emerging Therapeutic LandscapeSemantic proximity Read ↗

Novel strategies to target the humoral alloimmune response.Semantic proximity Read ↗

Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple MyelomaSemantic proximity Read ↗

Phase I trial of a humanized, Fc receptor nonbinding anti-CD3 antibody, hu12F6mu in patients receiving renal allografts.Semantic proximity Read ↗

Investigation of novel therapeutic strategies in B cell and antibody mediated diseaseSemantic proximity Read ↗

FcεRIγ-negative NK cells persist in vivo and enhance efficacy of therapeutic monoclonal antibodies in multiple myelomaSemantic proximity Read ↗

Defining the phenotype of antibody-mediated rejection in kidney transplantation: Advances in diagnosis of antibody injury.Semantic proximity Read ↗

Treatment of Chronic Active Antibody-mediated Rejection in Renal Transplant Recipients – A single center retrospective studySemantic proximity Read ↗

CD38 as a Therapeutic TargetSemantic proximity Read ↗

Targeting CD38 with Daratumumab Monotherapy in Multiple MyelomaSemantic proximity Read ↗

Natural Killer Cells: Critical Effectors During Antibody-mediated Rejection of Solid Organ Allografts.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.